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Abstract
Background: Atrial fibrillation (AF) involves substantial electrophysiological, structural and contractile remodeling. We
hypothesize that characterizing gene expression might uncover important pathways related to AF.
Methods and Results: We performed genome-wide whole blood transcriptomic profiling (Affymetrix Human Exon 1.0 ST
Array) of 2446 participants (mean age 66±9 years, 55% women) from the Offspring cohort of Framingham Heart Study. The
study included 177 participants with prevalent AF, 143 with incident AF during up to 7 years follow up, and 2126
participants with no AF. We identified seven genes statistically significantly up-regulated with prevalent AF. The most
significant gene, PBX1 (P= 2.861027), plays an important role in cardiovascular development. We integrated differential
gene expression with gene-gene interaction information to identify several signaling pathways possibly involved in AF-
related transcriptional regulation. We did not detect any statistically significant transcriptomic associations with incident AF.
Conclusion: We examined associations of gene expression with AF in a large community-based cohort. Our study revealed
several genes and signaling pathways that are potentially involved in AF-related transcriptional regulation.
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Introduction
Atrial fibrillation (AF), the most common cardiac arrhythmia, is
characterized by electrophysiological, structural and contractile
remodeling typically in the left atrium [1–4]. Several disease
pathways might predispose to AF [5–7], and heritability plays a
role in its development [8–11]. Recently, genome-wide association
studies (GWAS) identified several genetic loci associated with AF
[12–14]. However, the mechanisms underlying the genetic
predisposition to AF susceptibility remain unknown.
Gene expression is a quantitative and heritable phenotype
mediated by the interplay of environmental and genetic factors
[15,16]. Both human and animal models indicate that AF has
profound effects on global gene expression [17–19]. Many of the
differentially expressed genes were involved in ion channels, which
play an essential role in the pathophysiology of AF initiation,
perpetuation and adaptation [19–22]. Expression of extracellular
signal-regulated kinases and angiotensin-converting enzyme were
increased in AF [23]. In addition, differential gene expression was
observed in patients with heart failure [24] and valvular heart
disease [25].
Identification of gene expression signatures may provide insights
into AF pathogenesis and suggest targets for therapeutic interven-
tion. Prior transcriptomic studies were generally limited to small
groups of selected samples, which might not represent AF in the
community. We aimed to investigate associations of AF with gene
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expression in whole blood using a large community-based cohort.
We also investigated interactions between genes differentially
expressed in AF patients.
Methods
Study Samples
The Framingham Heart Study is a community-based observa-
tional cohort designed to investigate cardiovascular disease and its
risk factors. Since the study was initiated in 1948, three
generations of participants have been enrolled. A total of 5124
participants were enrolled in 1971 in the Offspring Cohort. It
consists of children of the Original Cohort and their spouses [26].
Every 4–8 years, Offspring participants complete a standardized
history and 12-lead ECG, blood tests and noninvasive tests. For
the present study, we focused on 2446 Offspring participants who
had RNA collected at the eighth examination (2005–2008). All
participants gave written informed consent. Our study was
approved by the Institutional Review Boards of National Human
Genome Research Institute and Boston University Medical
Center.
AF Ascertainment
At each examination, participants were asked about AF status.
In addition, their AF status and cardiovascular history were
solicited during surveillance interviews biennially [27,28]. We
included multiple sources to determine the presence of AF, such as
a 12-lead electrocardiogram from Framingham Heart Study
examination, and all cardiovascular disease-related hospitaliza-
tions and clinician visits. All electrocardiograms available from
study visits or in- and outpatient records were reviewed by study
cardiologists to adjudicate AF and atrial flutter events.
Gene Expression Profiling
The gene expression profiling has been described in detail by
Joehanes et al [29]. In brief, fasting peripheral whole blood was
collected during clinical visits. Total RNA was isolated from frozen
PAXgene blood tubes (PreAnalytiX, Hombrechtikon, Switzerland)
and amplified using the WT-Ovation Pico RNA Amplification
System (NuGEN, San Carlos, CA) according to the manufactur-
ers’ standard operating procedures. The obtained cDNA was
hybridized to the Human Exon 1.0 ST Array (Affymetrix, Inc.,
Santa Clara, CA). The raw data were quantile-normalized and
log2 transformed, followed by summarization using Robust Multi-
array Average [30]. The data were further adjusted for batch
effects and technical covariates, including the first principle
component of the expression data, batch effect, and the all-
probeset-mean residual. We also adjusted gene expression for the
complete blood counts, which were imputed from more than 2000
samples from the Third Generation cohort as previously described
[29]. We also measured the RNA Integrity Number in almost all
samples using an automated method (Asuragen Inc, Austin, TX),
and tested the inclusion of the RNA Integrity Number and RNA-
related measures as technical covariates, but did not find them
statistically significant. We therefore did not include them in our
models for this study. Our analysis focused on the ‘‘core’’ probe
sets, which were defined as the most reliable probe sets derived
from RefSeq and GenBank records. The gene and exon
annotations were obtained from Affymetrix NetAffx Analysis
Center (version 31). We excluded exons with signals lower than the
background, and transcript clusters that were not mapped to
RefSeq transcripts. We studied 287,329 probesets, corresponding
to 209,699 exons and 17,873 distinct transcripts for downstream
analysis.
Statistical Analyses
Our primary analysis used prevalent AF cases – AF diagnosed
before the blood sample for RNA was drawn. The association
between gene expression and AF was assessed by linear mixed
effect models to account for familial correlation between
Framingham Heart Study Offspring participants. We regressed
gene expression on AF status, and adjusted for age and sex.
Significant hits were adjusted for additional AF risk factors [31],
including smoking, height, weight, systolic blood pressure, diastolic
blood pressure, prevalent diabetes mellitus, prevalent myocardial
infarction, prevalent heart failure and antihypertensive treatment.
In secondary analyses, we studied associations of gene expression
with incident AF using used Cox proportional hazards models
with robust sandwich estimators and clustering by pedigree,
censoring at the last follow-up time or death. We also examined
the correlation of gene expression with various medications,
including warfarin, beta blocker, digoxin, and calcium channel
blocker. The gene expression was treated as the outcome, whereas
the usage of medication was treated as dichotomous independent
variables. To adjust for multiple testing, false discovery rate (FDR)
[32] was used, and statistical significance was claimed if FDR was
Table 1. Clinical characteristics of the sample.
Characteristics No AF (n=2,126) Prevalent AF (n =177) Incident AF (n =143)
Women, n (%) 1224 (58%) 63 (36%) 56 (39%)
Age, year 6 SD 6669 7368 7168
Smoker, n (%) 186 (9%) 7 (4%) 11 (8%)
Height, inches 6 SD 6664 6764 6664
Weight, pound 6 SD 174639 186642 181641
Systolic blood pressure, mm Hg 128617 128620 137619
Diastolic blood pressure, mm Hg 74610 69611 72610
Prevalent diabetes mellitus, n (%) 317 (15%) 56 (32%) 40 (28%)
Prevalent myocardial infarction, n (%) 22 (1%) 41 (23%) 7 (5%)
Prevalent heart failure, n (%) 67 (3%) 45 (25%) 9 (6%)
Antihypertensive treatment, n (%) 971 (46%) 129 (73%) 94 (66%)
doi:10.1371/journal.pone.0096794.t001
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less than 0.05. All analyses were performed using R software
package (www.r-project.org/).
Construction of Interaction Subnetwork Associated with
AF
We applied a dense module searching strategy [33] to identify
modules enriched with AF-related genes. The protein-protein
interaction data were obtained from the PINA database [34],
which was compiled from multiple protein-protein interaction
databases. All genes were included into analyses and assigned as
the seed gene once. Briefly, each gene was assigned a score to
represent its association with AF. The module searching started
from a single seed gene. Neighboring genes were added
sequentially to the module if the adding increased the overall
module score [35], which was defined as Zm~
P
giﬃﬃ
k
p , where k was
the number of genes in the module, and gi was the score of gene i.
The searching stopped if no genes could be added. Ingenuity
Pathway Analysis tool (Ingenuity Systems, Redwood, CA) was
then used to examine the enrichment of all module genes in each
canonical pathway, and the significance was claimed if its FDR
[32] was less than 0.05.
Results
Differential Gene Expression
Descriptive characteristics for 2446 eligible participants (mean
age 66±9 years, 55% women) are provided in Table 1. We
observed 177 prevalent cases who developed AF before examina-
tion 8 when their blood was collected for RNA extraction
(prevalent AF), and 143 additional AF cases who developed AF
after their RNA was collected (incident AF). The reference group
consisted of 2126 participants who had not developed AF by the
last follow-up in 2012. Figure 1 is the volcano plot showing the
association of all the studied genes with prevalent AF. As listed in
Table 2, with FDR,0.05, seven genes were significantly
associated with prevalent AF; all were over-expressed in prevalent
AF. The most significant gene, PBX1 (P=2.861027,
FDR=0.005), encodes a transcriptional factor belonging to the
PBX homeobox family. The most significant decreased expression
gene was REL (P=2.661024, FDR=0.14), which did not reach
the significance cutoff. We then tested the association of these
genes with prevalent AF adjusting for additional AF risk factors
[31], including smoking, height, weight, systolic blood pressure,
diastolic blood pressure, prevalent diabetes mellitus, prevalent
myocardial infarction, prevalent heart failure and antihypertensive
treatment. As shown in Table S1 in File S1, the associations of
these genes were attenuated, but they still reached the nominal
significance cutoff (P,0.05).
In our secondary analysis, we performed the association of gene
expression with incident AF adjusted for age and sex. No genes
reached the significance cutoff (FDR,0.05) (Table S2 in File
S1). The most significant gene was GPCPD1 (P=1.561025,
FDR=0.27). The volcano plot of gene expression with incident
AF is shown in Figure S1 in File S1.
Since Affymetrix Exon ST1.0 Array is able to profile
transcriptomic signatures at the exon level, we also studied the
association of each exon expression with prevalent AF. Table S3
in File S1 shows the top prevalent AF-related exons, and the
Table S4 in File S1 shows the association of each exon within
the seven AF-related genes. Interestingly, the seventh exon of
PBX1 was also the most significant exon associated with prevalent
AF (P=3.561027), suggesting that the exon has the mostT
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significant differential expression between prevalent AF cases and
controls.
We also performed additional analyses to study the correlation
of gene expression with various medications, including warfarin,
beta blocker, digoxin, and calcium channel blocker. We found that
warfarin, beta blocker, digoxin, and calcium channel blocker have
3, 287, 0, and 166 significant genes respectively (FDR,0.05); the
most significant genes for each medication are shown in the Table
S5 in File S1.
In order to further characterize transcriptomic signatures
associated with prevalent AF, we stratified samples with prevalent
AF based on their status during the blood draw: sinus rhythm
Figure 1. Volcano plot of expression association with prevalent AF. Each dot represents one gene. The x-axis represents the effect of each
gene, whereas the y-axis represents the log10 (P value). Positive effects represent that the genes were over-expressed in prevalent AF, while negative
effects represent that the genes had decreased expression with prevalent AF. Seven genes that reached the significant cutoff (FDR,0.05) were
marked.
doi:10.1371/journal.pone.0096794.g001
Table 3. Most significant canonical pathways enriched with genes in the AF subnetwork (FDR,0.005).
Canonoical pathway FDR Ratio+ Genes in the AF subnetwork
Antiproliferative Role of TOB in T Cell Signaling 3.561029 6/26 (0.23) SMAD2, CCNA2, PABPC4, CUL1, CDKN1B, SKP2
Hypoxia Signaling in the Cardiovascular System 1.161026 6/67 (0.09) HSP90B1, JUN, COPS5, HSP90AA1, HIF1A, UBE2D3
Cyclins and Cell Cycle Regulation 3.661026 6/90 (0.07) CCNA2, PA2G4, CUL1, BTRC, CDKN1B, SKP2
Cell Cycle: G1/S Checkpoint Regulation 1.761025 5/67 (0.07) PA2G4, CUL1, BTRC, CDKN1B, SKP2
Protein Ubiquitination Pathway 5.461025 8/264 (0.03) USP7, HSP90B1, HSPA9, CUL1, HSP90AA1, BTRC, UBE2D3, SKP2
Aryl Hydrocarbon Receptor Signaling 8.761025 6/148 (0.04) CCNA2, HSP90B1, JUN, NEDD8, HSP90AA1, CDKN1B
Estrogen-mediated S-phase Entry 2.561024 3/27 (0.11) CCNA2, CDKN1B, SKP2
Prostate Cancer Signaling 9.161024 4/94 (0.04) HSP90B1, PA2G4, HSP90AA1, CDKN1B
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 1.561023 3/49 (0.06) CUL1, BTRC, SKP2
HIF1a Signaling 2.061023 4/105 (0.04) JUN, COPS5, HSP90AA1, HIF1A
Glucocorticoid Receptor Signaling 2.361023 6/280 (0.02) SMAD2, HSP90B1, JUN, HSPA9, PBX1, HSP90AA1
EIF2 Signaling 2.661023 5/192 (0.03) RPL15, EIF2AK1, RPL4, RPL22, RPS18
eNOS Signaling 4.861023 4/136 (0.03) CCNA2, HSP90B1, HSPA9, HSP90AA1
+Ratio is the number of genes within AF subnetwork comparing to the total number of genes in the pathway.
doi:10.1371/journal.pone.0096794.t003
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(n = 115) and AF (n= 62). As shown in the Table S6 in File S1,
all seven prevalent AF-related genes were associated with both
sinus rhythm and AF (nominal P,0.05), although the association
was attenuated due to the reduced sample size and limited power.
Gene Interaction Network Associated with AF
We applied a dense module searching strategy [33] to identify
modules containing genes with strong association with AF. Each
module represents a group of interacting genes; the nodes
represent genes, and the edges represent interactions between
genes. A total of 7993 modules were identified. Given the highly
overlapping nature of modules and the enrichment of significant
modules, we merged the top 1% modules with highest scores as
previously suggested [33] and considered it as an AF subnetwork
(Figure 2). The subnetwork consisted of 106 nodes and 360 edges.
The most significant gene, PBX1, was included in the subnetwork.
In order to further characterize the function of AF subnetwork,
we applied Ingenuity Pathway Analysis to study the gene
enrichment in canonical pathways. Twenty-two canonical path-
ways were significantly enriched with genes in the AF subnetwork
(FDR,0.05). The most significant pathways were antiproliferative
role of transducer of ERBB2 (TOB) in T Cell Signaling
(FDR=3.561029) and hypoxia signaling in the cardiovascular
system (FDR=1.161026) (Table 3).
Discussion
Gene expression is considered an important bridge to connect
genetic variations and diseases [15,36]. We performed genome-
wide whole blood transcriptomic profiling of 177 participants with
prevalent AF and more than 2000 AF-free participants from the
Framingham Heart Study Offspring cohort. Seven genes were up-
regulated in samples with prevalent AF after adjustment for
multiple testing, but none of them were reported in prior studies
[17–23,37], suggesting the complexity of gene regulation network
underlying AF. We did not identify any transcriptomic signatures
significantly associated with incident AF.
The most significant gene was PBX1, which encodes a
homeodomain transcription factor. The gene plays an important
role in cardiovascular development, and orchestrates separate
transcriptional pathways to control great-artery patterning and
Figure 2. AF subnetwork derived from protein-protein interaction. Each node represents one gene, wheras each edge represents the
interaction between two genes. The nodes were colored to represent their association with AF: red color represents strong association, and white
color represents no association. The node size is proportional to the number of edges that the node connects to.
doi:10.1371/journal.pone.0096794.g002
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cardiac outflow tract septation [38]. The inactivation of PBX1
results in persistent truncus arteriosus in mice [39]. Another
significant gene, SLC7A1, encodes a high affinity cationic amino
acid transporter that participates in the total carrier-mediated
uptake activity [40]. A polymorphism in the 39-UTR of SLC7A1
was found to be associated with hypertension and endothelial
dysfunction [41], probably due to the binding of miR-122 to the
region [42].
Beyond the individual gene association, we also studied the
combined association of differential gene expression with AF.
Increasing evidence has suggested that the development of AF
might result from the disruption of multiple biological pathways
[5–7,43]. We constructed an AF subnetwork by taking advantage
of a wealth of protein-protein interaction information that was
collected in several databases over years. The subnetwork was
highly enriched with genes involved in multiple signaling
pathways, including hypoxia signaling pathway in the cardiovas-
cular system and the TOB antiproliferative signaling pathway.
The hypoxia signaling pathway is key to a series of molecular
events to response to the local oxygen tension in the cardiovascular
system [44,45]. The pathway is also involved in the myocardial
remodeling [46] and the activation of angiogenic growth factors
[47]. The TOB antiproliferative signaling pathway regulates T cell
proliferation and cytokine transcription, which could avoid
excessive T cell response and thus reduce the risk of autoimmune
disorders or tissue injury [48]. Multiple genes in the pathways are
involved in attenuated cardiomyocyte hypertrophy and congenital
heart diseases [49,50]. Our analyses provide an approach to
translate individual gene associations into a broader picture of
transcriptomic profiles, which might be associated with the
prevalence or onset of AF.
There are several limitations in our study. We found no
significant transcriptomic signatures associated with incident AF,
although the sample size was similar to that of prevalent AF. The
mechanisms contributing to the discrepancy are unclear. We
speculate that the discrepancy may be due to different signaling
pathways underlying the onset and perpetuation of AF: genes
associated with incident AF might be responsible for the initiation
of AF, whereas genes associated with prevalent AF might be
responsible for the maintenance of AF. Given that RNA was only
collected at the eighth examination of the Offspring cohort but not
any earlier examinations, it is infeasible to examine the longitu-
dinal changes of transcriptomic signatures for the same partici-
pants. Gene expression varies in different tissue types. The
transcriptional profiles in this study were measured on whole
blood, but the ideal tissue for study AF is the left atrium. However,
invasive left atrial specimen collection is unfeasible in a commu-
nity-based study, and would result in highly selected samples [51]
and few controls. In addition, the cross-hybridization in micro-
array based platforms might result in non-specific signals for some
genes, thus a further validation by RT-PCR or RNA sequencing
would be helpful to rule out potential false associations [52,53]. As
a proof-of-concept, we performed RT-PCR on 95 coronary heart
disease-related genes in 429 samples selected for a pilot study [29].
As shown in the Table S7 in File S1, the expression of 49 out of
95 genes was correlated well between microarray and RT-PCR
(Pearson’s correlation coefficient .0.5), and 91 genes have the
same direction of effect, suggesting robustness of our assay,
although it is not a direct validation of top hits for AF. Given that
thousands of tests were conducted and the lack of external
replications, it is possible that some findings might be false
positives even if we used very stringent Bonferroni correction.
Because of the observational study design, the associations we
observed do not prove causation. Moreover, the participants were
middle-age to older adults, largely of European descent, raising
uncertainty regarding generalizability to other ethnicities/races.
Our current study did not distinguish between atrial fibrillation
and atrial flutter, nor patterns of AF, which might have unique
gene expression profiles. Future analyses with stratification of
rhythm types might uncover unique gene expression profiles
specific to each rhythm type.
In conclusion, we examined the association of whole blood gene
expression with AF in a large community-based cohort. Our study
revealed that several genes and signaling pathways might be
activated in prevalent AF and may be involved in AF mainte-
nance. Future increase of sample size, longer follow up, and
external validation would help to identify additional transcription
signatures associated with AF and might provide valuable insights
into AF pathogenesis [54].
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